Based on the Milestone Pharmaceuticals Inc stock forecast from 1 analysts, the average analyst target price for Milestone Pharmaceuticals Inc is USD 9.00 over the next 12 months. Milestone Pharmaceuticals Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Milestone Pharmaceuticals Inc is Bearish, which is based on 1 positive signals and 7 negative signals. At the last closing, Milestone Pharmaceuticals Inc’s stock price was USD 0.83. Milestone Pharmaceuticals Inc’s stock price has changed by +27.72% over the past week, -61.57% over the past month and -52.61% over the last year.
No recent analyst target price found for Milestone Pharmaceuticals Inc
No recent average analyst rating found for Milestone Pharmaceuticals Inc
Company Overview Milestone Pharmaceuticals Inc
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which completed Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montréal, Canada. Read Less
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which complete...Read More
Frequently Asked Questions About Milestone Pharmaceuticals Inc (MIST) Stock
Based on ratings from 1 analysts Milestone Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 1 buy, sell and hold ratings.
Unfortunately we do not have enough data on MIST's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for MIST is USD 9.00 over the next 12 months. The maximum analyst target price is USD 9 while the minimum anlayst target price is USD 9.
Unfortunately we do not have enough data on MIST's stock to indicate if its overvalued.
The last closing price of MIST's stock was USD 0.83.
The most recent market capitalization for MIST is USD 0.04B.
Based on targets from 1 analysts, the average taret price for MIST is projected at USD 9.00 over the next 12 months.
This means that MIST's stock price may go up by +979.14% over the next 12 months.
We can't find any ETFs which contains Milestone Pharmaceuticals Inc's stock.
As per our most recent records Milestone Pharmaceuticals Inc has 33 Employees.
Milestone Pharmaceuticals Inc's registered address is 1111 Dr. Frederik-Philips Boulevard, Montreal, QC, Canada, H4M 2X6.
You can get more information about it from Milestone Pharmaceuticals Inc's website at https://www.milestonepharma.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Frequently Asked Questions About Milestone Pharmaceuticals Inc (MIST) Stock
Based on ratings from 1 analysts Milestone Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 1 buy, sell and hold ratings.
Unfortunately we do not have enough data on MIST's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for MIST is USD 9.00 over the next 12 months. The maximum analyst target price is USD 9 while the minimum anlayst target price is USD 9.
Unfortunately we do not have enough data on MIST's stock to indicate if its overvalued.
The last closing price of MIST's stock was USD 0.83.
The most recent market capitalization for MIST is USD 0.04B.
Based on targets from 1 analysts, the average taret price for MIST is projected at USD 9.00 over the next 12 months.
This means that MIST's stock price may go up by +979.14% over the next 12 months.
We can't find any ETFs which contains Milestone Pharmaceuticals Inc's stock.
As per our most recent records Milestone Pharmaceuticals Inc has 33 Employees.
Milestone Pharmaceuticals Inc's registered address is 1111 Dr. Frederik-Philips Boulevard, Montreal, QC, Canada, H4M 2X6.
You can get more information about it from Milestone Pharmaceuticals Inc's website at https://www.milestonepharma.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for MIST !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
